Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Other Operating Expenses (2020 - 2025)

Lyell Immunopharma's Other Operating Expenses history spans 6 years, with the latest figure at $1.6 million for Q3 2025.

  • For Q3 2025, Other Operating Expenses rose 117.95% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $1.2 million, down 66.22%, while the annual FY2024 figure was $3.3 million, 18.6% up from the prior year.
  • Other Operating Expenses for Q3 2025 was $1.6 million at Lyell Immunopharma, up from -$1.1 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $1.6 million in Q3 2025 and bottomed at -$1.1 million in Q2 2025.
  • The 5-year median for Other Operating Expenses is $758000.0 (2021), against an average of $727631.6.
  • The largest annual shift saw Other Operating Expenses skyrocketed 425.11% in 2022 before it plummeted 208.81% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $798000.0 in 2021, then soared by 51.63% to $1.2 million in 2022, then crashed by 47.02% to $641000.0 in 2023, then decreased by 19.97% to $513000.0 in 2024, then skyrocketed by 210.14% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Other Operating Expenses are $1.6 million (Q3 2025), -$1.1 million (Q2 2025), and $119000.0 (Q1 2025).